Skip to main content
C.Q. Pharmaceutical Holding Co., Ltd. logo

C.Q. Pharmaceutical Holding Co., Ltd. — Investor Relations & Filings

Ticker · 000950 ISIN · CNE0000010K0 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,883 across all filing types
Latest filing 2025-09-29 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 000950

About C.Q. Pharmaceutical Holding Co., Ltd.

https://www.cqphar.com

C.Q. Pharmaceutical Holding Co., Ltd. is a comprehensive pharmaceutical enterprise specializing in the distribution, retail, and supply chain management of healthcare products. The company operates an extensive network focused on the wholesale of pharmaceuticals and medical devices, providing integrated logistics and warehousing solutions to healthcare providers and manufacturers. Its core business activities encompass the procurement and distribution of a wide range of prescription drugs, over-the-counter medications, and specialized medical equipment. Through its retail pharmacy operations and third-party logistics services, the company facilitates the efficient delivery of medical supplies. C.Q. Pharmaceutical Holding Co., Ltd. emphasizes technological integration within its supply chain to optimize inventory management and ensure the integrity of healthcare products throughout the distribution lifecycle.

Recent filings

Filing Released Lang Actions
关于召开2025年第四次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 fourth extraordinary general meeting of shareholders (临时股东会) for Chongqing Pharmaceutical Holdings Co., Ltd. It details the meeting date, voting procedures, registration, and agenda items. It does not contain financial statements or results but is an announcement of a shareholder meeting and related voting information. The document length is about 3500 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-09-29 Chinese
第九届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 9th Board of Directors of the company 重药控股股份有限公司. It details the meeting date, attendance, agenda items, voting results, and references related announcements. The content focuses on board decisions and governance matters, such as approval of related party transaction limits, guarantee adjustments, and calling an extraordinary shareholders meeting. There is no financial data, earnings information, or report publication mentioned. The document is clearly about board/management information, specifically board meeting resolutions and decisions. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing fallback. Confidence is high due to clear keywords like '董事会会议决议公告' (Board meeting resolution announcement) and detailed voting results on board matters.
2025-09-29 Chinese
关于参加重庆辖区上市公司2025年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor reception day event organized under the guidance of the Chongqing Securities Regulatory Bureau. It details the event's date, time, and participation method, emphasizing investor relations and interaction. The document does not contain financial statements, audit information, voting results, or any report publication. It is a regulatory announcement related to investor relations activities but does not fit into categories like earnings release, annual report, or call transcript. Given its nature as a formal announcement without substantive financial data or report content, it best fits the Regulatory Filings (RNS) category as a general regulatory announcement.
2025-09-16 Chinese
关于控股股东股权结构拟发生变更的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a change in the equity structure of the company's controlling shareholder. It details the transfer of shares, the parties involved, transaction amounts, and the impact on control and ownership. The document is relatively short (1034 characters) and does not contain financial statements or detailed financial analysis. It is an update on a capital structure change rather than a full financial report or a regulatory filing about a report publication. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-09-15 Chinese
关于子公司药物获临床试验批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Chongqing Pharmaceutical Holdings Co., Ltd. regarding the approval of clinical trials for a drug by its subsidiary. It includes details about the drug, regulatory approval from the National Medical Products Administration, and risk disclosures. The document is short (1015 characters) and serves as an official announcement of a regulatory event related to drug clinical trial approval. It does not contain financial data, management discussion, or detailed financial reports. It is not an annual or interim report, earnings release, or any form of financial filing. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-09-10 Chinese
关于回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with regulatory rules. The document is relatively short (1256 characters) and focuses on the update of the share buyback activity rather than a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion. The content matches the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback of its own shares.
2025-09-02 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.